ESC HF 2017 Enrollment of ineligigle patients in the TRUE-AHF study may have undermined the ability of the trial to demonstrate a benefit of ularitide in patients with acute heart failure.
ESC HF 2017 A 48-hour infusion of serelaxin did not improve CV mortality through 180 days or worsening HF through 5 days, in patients with acute heart failure in the RELAX-AHF-2.
In a large randomised Vitamin D Assessment Study, monthly high-dose vitamin D supplementation was not associated with a lower cardiovascular risk.
In the phase 2 study SOCRATES-PRESERVED, vericiguat did not change the primary endpoints of NT-proBNP and left atrial volume compared with placebo, in patients with HFpEF.
RG7652, a PCSK9 antibody, dose-dependently reduced LDL-c, ApoB and Lp(a), but not inflammatory proteins, without concerning adverse events.
ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.
Data from ’The Aragon Workers' Health Study presented during the EAS congress revealed that adherence to the Mediterranean diet was associated with less plaque in the carotid, femoral arteries and aorta.
PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.
In the SPRINT trial, targeting an SBP of <120 mmHg, as compared with <140 mmHg, significantly reduced the risk of developing ADHF by 36% in all predetermined subgroups.
ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.
At the EAS congress, data of the Copenhagen General Population Study demonstrated that patients with familial hypercholesterolaemia have increased risk of ischemic stroke compared to reference patients.
A Consensus Panel of the European Atherosclerosis Society (EAS) published a statement that shows that the total evidence on LDL-lowering fulfils the criteria for a causal role of LDL-c in atherosclerotic vascular disease.